Navidea Biopharmaceuticals Inc.
NAVB
NAVB was delisted on the 5th of October, 2023.
26 hedge funds and large institutions have $1.08M invested in Navidea Biopharmaceuticals Inc. in 2022 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 3 closing their positions.
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
4% more funds holding
Funds holding: 25 → 26 (+1)
10% less capital invested
Capital invested by funds: $1.19M → $1.08M (-$114K)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
83% less call options, than puts
Call options by funds: $39K | Put options by funds: $233K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Simplex Trading
Chicago,
Illinois
|
+$21.5K |
| 2 |
TSS
Two Sigma Securities
New York
|
+$11.5K |
| 3 |
Renaissance Technologies
New York
|
+$10.7K |
| 4 |
PP
PDS Planning
Dublin,
Ohio
|
+$8.97K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$6.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$45.2K |
| 2 |
ACM
Allred Capital Management
Dallas,
Texas
|
-$12.6K |
| 3 |
VF
Virtu Financial
New York
|
-$11K |
| 4 |
Two Sigma Advisers
New York
|
-$9K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.37K |
NAVB Hedge Fund Activity: Q2 2022 in Review
26 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Navidea Biopharmaceuticals Inc. (NAVB) for Q2 2022, worth a combined $1.08M — down 9.5% from $1.19M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new NAVB positions and 3 closed out — a net gain of 1 holder — while 4 added to existing stakes and 5 trimmed.
The largest buyer was Simplex Trading, adding an estimated $21.5K. The largest seller was BlackRock, cutting an estimated $45.2K.
- 26 institutional investors held Navidea Biopharmaceuticals Inc. (NAVB) as of Q2 2022, up from 25 in Q1 2022.
- Funds reported $1.08M of Navidea Biopharmaceuticals Inc. stock for Q2 2022, down 9.5% quarter-over-quarter.
- 4 funds opened new Navidea Biopharmaceuticals Inc. positions in Q2 2022 and 3 closed out, a net change of +1 holder.
- The largest Navidea Biopharmaceuticals Inc. buyer in Q2 2022 was Simplex Trading, an estimated $21.5K added.
- The largest Navidea Biopharmaceuticals Inc. seller in Q2 2022 was BlackRock, an estimated $45.2K sold.
Based on aggregated 13F filings for Q2 2022.